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Abstract
Epigenetic events are critical contributors to the pathogenesis of cancer, and targeting epigenetic mechanisms represents a
novel strategy in anticancer therapy. Classic demethylating agents, such as 5-Aza-29-deoxycytidine (Decitabine), hold the
potential for reprograming somatic cancer cells demonstrating high therapeutic efficacy in haematological malignancies.
On the other hand, epigenetic treatment of solid tumours often gives rise to undesired cytotoxic side effects. Appropriate
delivery systems able to enrich Decitabine at the site of action and improve its bioavailability would reduce the incidence of
toxicity on healthy tissues. In this work we provide preclinical evidences of a safe, versatile and efficient targeted epigenetic
therapy to treat hormone sensitive (LNCap) and hormone refractory (DU145) prostate cancers. A novel Decitabine
formulation, based on the use of engineered erythrocyte (Erythro-Magneto-Hemagglutinin Virosomes, EMHVs) drug delivery
system (DDS) carrying this drug, has been refined. Inside the EMHVs, the drug was shielded from the environment and
phosphorylated in its active form. The novel magnetic EMHV DDS, endowed with fusogenic protein, improved the stability
of the carried drug and exhibited a high efficiency in confining its delivery at the site of action in vivo by applying an
external static magnetic field. Here we show that Decitabine loaded into EMHVs induces a significant tumour mass
reduction in prostate cancer xenograft models at a concentration, which is seven hundred times lower than the therapeutic
dose, suggesting an improved pharmacokinetics/pharmacodynamics of drug. These results are relevant for and discussed in
light of developing personalised autologous therapies and innovative clinical approach for the treatment of solid tumours.
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Introduction
Prostate cancer (PC) is a commonly diagnosed malignancy in
developed countries and its incidence dramatically increases with
age [1,2]. Despite the proven success of hormonal therapy,
surgical castration [3,4] and radiation therapy [5–7], however
after being managed a subset of patients manifest disease
progression and became resistance to further hormonal manipu-
lation [8–10]. Up to 20% of PC patients treated with radical
prostatectomy have the probability to progress to invasive cancer
with relapsed metastatic conditions within 5 to 10 years [11]. The
median survival of patients with metastatic PC is 12–16 months
from the time of diagnosis to death [12]. No curative treatments
are available at this stage of the disease. In spite of intensive
research efforts, the molecular mechanisms by which prostate
cancer cells become resistant to hormone therapy remain poorly
characterized.
Epigenetic alterations, involving hypermethylation of genes in
critical pathways, such as DNA repair, metabolism, and invasion/
metastasis, have been found in prostatic cancer providing new
information of the pathogenesis of this tumour [13,14]. Post-
translational changes weakening chromatin structure alter gene
expression and lead cells to metastatic spreading. However, as
epigenetic modifications do not require changing in DNA
sequence they are potentially reversible. DNA methyltransferases
(DNMTs) involved in the epigenetic silencing of gene expression
become therefore a suitable target for epigenetic treatments [15–
17].
Decitabine (5-Aza-2’-dC) is a classic demethylating agent
approved by FDA for the treatment of patients with myelodys-
plastic syndromes and Acute Lymphoblastic Leukemia (ALM)
[18]. However, the beneficial of Decitabine treatment remains
uncertain for patients with solid tumours as the lack of chemical
stability in aqueous solution and high incidence of neutropenia
have been associated with its use.
Recently the anti-proliferative effect of Decitabine has been
tested in different tumour histotypes such as testicular [19], lung
[20], breast [21], colorectal cancer cells [22], CNS tumours [23]
and prostate cancer [24–26]. These encouraging results indicated
that Decitabine could be effective in inhibiting cancer progression
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and inducing cell differentiation. Notwithstanding these in vitro
reports, it was emphasised the need for improving drug stability in
solution and delivery efficacy, to minimise toxic side effects and
prolong epigenetic outcomes in vivo.
The remarkable therapeutic potential of Decitabine is in fact
hampered by its systemic instability [27]. Its low therapeutic index
and the difficulty to calibrate steady state blood concentration
have affected several clinical studies.
In recent years drug delivery systems (DDSs) have been
developed to improve the specific and localized delivery of
therapeutic agents to target tumour tissue while avoiding severe
toxic side effects on healthy organs [28,29]. Cell-based drug
delivery systems such as erythrocytes are particularly attractive
tools for delivering several classes of therapeutics. Erythrocytes are
safe and biocompatible carriers that can accommodate molecules
of different size, nature and stability and they are particularly
useful for those agents that show limited tissue penetration or are
rapidly inactivated upon i.v. in vivo administration [30–32].
Moreover, erythrocytes also act as circulating bioreactors
converting a pro-drugs into its active forms.
A novel erythrocyte-based drug delivery system, endowed with
both super-paramagnetic nanoparticles (NPs) inside the erythro-
cytes and a fusogenic glycoprotein, the filamentous hemagglutinin
(FHA), inserted into the cytoplasmic membranes of erythrocytes
(Erythro-Magneto-Hemagglutinin Virosomes, EMHVs), was re-
cently patented (WO2010/070620(A1)).
It has been shown that these EMHV improved kinetics of
therapeutic compounds into target cells in vitro. Efficient drug
intracellular release is achieved into host cells due to presence of
fusogenic glycoprotein on EMHV membranes [33,34].
The magnetic nature of this drug delivery system allows EMHV
to be directed toward the desired tissues/organs in vivo upon the
application of an external magnetic field.
Here we tested a target ‘‘epigenetic therapy’’ based on use of
low dose 5-Aza-2’-dC loaded into EMHVs in two prostate cancer
models. Human prostate adenocarcinoma LNCap cells, responsive
to hormone therapy, and DU145, hormone refractory cells, have
been used [35] in vitro and in vivo in xenograft tumour models. We
show that the pharmacological anticancer activity of 5-Aza-29-dC
is highly increased by our EMHVs delivery system both in vitro and
in vivo suggesting its possible application in future clinical trials.
Materials and Methods
Reagents
Superparamagnetic nanoparticles (NPs) were purchased from
nano-screenMAG, Chemicell, Berlin, Germany. Filamentous
Hemagglutinin from Bordetella pertussis (FHA), 5-aza-29-deoxicyti-
tidine (5-Aza-2’-dC), HPLC grade acetonitrile, N9,N9-dimethyl-
hexylamine (DMHA), cytidine-59-triphosphate disodium salt
(CTP) and 2’-deoxyuridine (dU) were purchased from Sigma-
Aldrich, Milan, Italy. Methanol and ammonium acetate were
purchased from Carlo Erba, Milan, Italy.
Preparation of 5-Aza-2’-dC-loaded EMHVs (A-EMHVs)
Human erythrocytes were prepared by gradient centrifugation
at 400 g for 30 minutes and then washed twice in 1X PBS (1.37 M
NaCl, 57 mM KCl, 54 mM Na2HPO4, 45 mM KH2PO4
pH 7.4). 26109 erythrocytes were lysed in 250 ml lysis buffer 1
(10 mM TRIS, 0.1 mM EDTA, 1 mM MgCl2 pH 7.2) for 60
minutes at 0uC. The isotonicity was then restored by adding
130 ml of resealing buffer (65 ml of 10X PBS pH 7.4 and 65 ml of
15 mM MgCl2 pH 7.4), supplemented with 2 mg of FHA, 0.1 mg
of 100 nm super-paramagnetic NPs and 75 mg of 5-Aza-2’-dC.
The suspension was incubated for 45 minutes at 37uC under
mild agitation to promote resealing and obtain engineered
erythrocytes loaded with 5-Aza-29-dC (A-EMHVs). A-EMHVs
were then collected by centrifugation at 8,000 g for 15 minutes at
4uC. Successively the erythrocyte suspension was washed twice
with 1X PBS by centrifugation at 8,000 g for 15 minutes at 4uC,
re-suspended in 1X PBS and conserved at 4uC until used.
Cell culture
LNCap and DU145 prostate cancer cell lines were obtained
from American Type Culture Collection (ATCC, Rockville, MD)
and maintained in culture medium RPMI 1640 supplemented
with 10% Fetal Bovine Serum, 2 mM L-glutamine, in presence of
100 U/ml penicillin-streptomycin, at split ratio of 1:3 twice a
week. These prostate cancer cells were used for both in vitro and in
vivo experiments.
Confocal Laser Scanning Microscopy (CLSM) analysis
DU145 cells at a density of 1.56105 were seeded in 6-well
microtiter plates. On the bottom of the culture plates glass
coverslips were placed on which the cells were let to grow until 60–
80% confluence. After 24 hours, the culture medium was replaced
with media containing 1.56108 A-EMHVs. In a sample, fresh
medium was replaced with no adding of EMHVs to visualize naı¨ve
cell structure (control). After 6, 24 and 48 hours of incubation,
coverslips were retrieved and cells were washed in 1X PBS buffer
and fixed with 4% paraformaldehyde. Cell nuclei were counter
stained with DAPI, washed with 1X PBS and the whole coverslip
is mounted on a slide using anti-fade medium. Fluorescence and
bright-field images were captured by CSLM, Leica TCS SP5
inverted microscope system, equipped with sources emitting from
the UV to the visible. DAPI fluorescence was detected using
excitation at 405 nm and recording emission at 454 nm while the
red fluorescence of super-paramagnetic NPs was excited at
543 nm and its emission was detected at 613 nm.
Liquid chromatography–mass spectrometry (HPLC-MS)
analysis of 5-Aza-2’-dC loaded into EMHVs
To quantify the total amount of 5-Aza-2’-dC inside the
modified erythrocytes, 26109 freshly prepared A-EMHVs were
lysed in 200 ml of lysis buffer 2 (155 mM NH4Cl, 10 mM
KHCO3, 0.1 mM EDTA, pH 7.2) for 10 minutes at room
temperature and then centrifuged at 12,000 g for 15 minutes at
4uC. The supernatant was transferred into a Microcon centrifugal
filter device with MWCO 30,000 Da (Amicon YM-10, Millipore,
Vimodrone MI, Italy) and then centrifuged at 14,000 g for
2 hours at 4uC. Filtered samples were kept at 280uC until
analysis. The HPLC system used was a Dionex 3,000 Ultimate
series LC (Sunnyvale, CA, USA) connected to a linear ion trap
LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientific,
USA), equipped with an electrospray ion source. Data were
acquired and processed with Excalibur 2.1 software. Compounds
were separated on a Mediterranea Sea18 reverse-phase column
(150 mm, 2.1 mm I.D. and 5 mm particle size) from Teknokroma
(Analytical Technology S.r.l., Brugherio Milan, Italy). The column
was set at a flow rate of 0.25 ml/minute, at a temperature of 36uC,
and sample volumes of 10 ml were injected. The mobile phase
consisted of 5 mM ammonium acetate (solvent A) and acetonitrile
(solvent B). The first 13 minutes were an isocratic run with solvent
A; between 13 and 20 minutes the percentage of mobile phase B
was increased to 35%, maintained for 2 minutes and then the
initial the mobile phase was re-established within 2 minutes. The
mass spectrometer was operated in positive electrospray mode and
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the collision energy was 35 eV. The transitions monitored were
m/z 229---.113 for 5-Aza-2’-dC; m/z 219---.103 for guany-
lurea derivatives; m/z 247---.131 for formulated derivatives of 5-
Aza-2’-dC. To search for possible phosphorylated forms of 5-Aza-
2’-dC, 26109 freshly prepared A-EMHVs were left at 37uC for
24 hours. Successively, samples were lysed and filtered as above
described and 400 ng of CTP were added to the samples as
internal standards. The mobile phase consisted of 20 mM DMHA
pH 7.0 (solvent A) and methanol-water 80:20 (solvent B). The first
12 minutes were an isocratic run with 10% solvent B; between 12
and 15 minutes the percentage of mobile phase B was increased to
80%, maintained for 1 minute and then the initial the mobile
phase was re-established within 2 minutes. The mass spectrometer
was operated in negative electrospray mode and the collision
energy was 15 eV. The transitions monitored were m/z 482---.
384 for CTP; m/z 467---.369 for 5-Aza-2’-dC triphosphate; m/z
387---.289 for 5-Aza-2’-dC diphosphate; m/z 307---.208 for 5-
Aza-2’-dC monophosphate corresponding to the elimination of a
neutral molecule of H3PO4. For the calibration curve, six different
CTP standard solutions were used. The peak area ratio of sample/
CTP was used for quantization.
Cytofluorimetric (FACS) analysis
LNCap and DU145 cells at a density of 1.56105 were seeded in
6-well microtiter plates for cell cycle assays. After 24 hours, the
culture medium was replaced with media containing: no drug
(CTRL); free 5-Aza-2’-dC at doses 6.8 mg or 120 ng; 1.56108 A-
EMHVs (containing approximately 120 ng 5-Aza-2’-dC).
After 24, 48 and 96 hours of incubation, control and treated
cells were harvested and analysed by FACS. Nuclei were stained
with 10 mg/ml propidium iodide (PI) in hypotonic solution (1X
PBS containing 0.1% sodium citrate and 0.1% Triton X-100) for
30 minutes at 4uC in the dark for assessment of cell cycle phases.
Apoptotic cells were detected by Annexin V test (BioVision).
The treated and untreated cells were suspended in 1X binding
buffer and incubated at room temperature for 15 minutes with
Annexin V-FITC and Propidium Iodide (PI) was added for nuclei
staining following manufacturer’s instructions.
Flow-cytometry was carried using Becton–Dickinson FACScan
CentroII and data were analysed by FlowJo software.
Animals
For the experiments carried out at the animal facility of
Marshall University, congenital athymic BALB/c Nude mice,
homozygous for the nu/nu allele, were bred in house. The colony
of 8- to 12-week-old male mice was developed from breeding stock
obtained from Charles Rivers Laboratories (Wilmington, MA).
These animals were used for LNCap xenograft experiments.
Animals used in experiment carried out at ‘‘Toscana Life
Sciences’’ animal facility were athymic Nude-Foxn1nu male mice,
6 weeks of age, purchased from Harlan Laboratories (Udine,
Italy). These animals were used for DU145 xenografts.
In both cases, animals were housed in micro-isolators in
autoclaved cages with polyester fiber filter covers, under germ-
free conditions. All food, water, and bedding were sterilized and
the animals were maintained in an ambient temperature of
2362uC in rooms having a 12 hours light/dark cycle.
X-ray imaging
Athymic BALB/c Nude mice were injected with 1.56108
EMHVs suspended in 150 ml of 1X PBS.
Following EMHVs tail vein injection, one group of animal
were exposed to external magnetic field by placing two earth
magnets on the lower lateral abdominal region for 30 minutes
(EMHVs-MF), while mice were kept under 2% isofluorane
anesthesia. Neodinium magnets (round shaped 5.0 mm) with
approximately coercive force of 1,000 KOersted, were used. A
control group of mice was tail vein injected with EMHVs as
previously described but no external magnetic field was applied
(EMHVs-NMF). One hour after the treatment, mice were
sacrificed by CO2 asphyxiation and the accumulation of ferrous
beads was assessed by X-ray imaging. The imaging analysis was
performed using a Philips DigitalDiagnost direct digital radiogra-
phy system with flat detector technology (Philips, Hamburg,
Germany) with a dose of 60 kVp at 5 mAs.
Tumour xenograft procedures
Both athymic BALB/c Nude and Nude-Foxn1nu mice were
anesthetized by 2.5% isoflurane during manipulation.
The setting of the models: LNCap or DU145 cells were
concentrated to 76106 or 4.56106 respectively in 1X PBS and
injected subcutaneously 1:1 with MatrigelTM basement mem-
brane matrix (BD Biosciences, Franklin Lakes, NJ) into the left
flank of each mouse (total volume 200 ml). Once xenografts started
growing, their sizes (mm3) were measured twice a week with digital
caliper and the volume was calculated by using the standard
formula: length x width2/2. Tumour xenografts were allowed to
grow approximately up to 100 mm3 and this volume was selected
as the initial stage for beginning the treatment. Mice were
randomized (n = 6), anesthetized and prepared for tail vein
injection with the selected treatment. Before each injection,
tumours were measured and compared to the corresponding
initial volumes, in order to normalize the data (X = 100 x
volume1/volume0). Randomisation: Mice were assigned to seven
different groups in both experimental settings (LNCap or DU145
xenografts) and they were treated as follow: 1X PBS (CTRL);
85 mg 5-Aza-2’-dC (2.5 mg/kg) (A1); 120 ng 5-Aza-2’-dC (A2);
1.56108 unloaded EMHVs in absence of static magnetic field
(EMHVs-NMF); 1.56108 unloaded EMHVs and static magnetic
field applied on tumour (EMHVs-MF); 1.56108 EMHVs
containing 120 ng 5-Aza-2’-dC (A-EMHVs-NMF); 1.56108
EMHVs containing 120 ng 5-Aza-2’-dC and static magnetic field
applied on tumour (A-EMHVs-MF).
Injection protocol: Mice were biweekly administered intrave-
nously with 150 ml treatment per inoculation, over 3 weeks. After
each injection in those groups selected to be treated also with static
magnetic field (EMHVs-MF and A-EMHVs-MF), two earth
magnets (1,000 KOersted) were applied to the xenograft mass
for 30 minutes to ensure intra-tumour accumulation. Mice were
then allowed recovering and monitored for signs of distress. At the
end of the treatment course or when the tumour volume reached
approximately 400 mm3, mice were sacrificed by CO2 asphyxi-
ation and the prostate tumour mass, liver, kidneys were harvested
and stored at -80uC until additional analysis.
Morphological and immunohistochemical analysis of
tumour xenografts
Frozen samples stored at -80uC were equilibrate at 220uC
overnight before sectioning by cryostat (Microm HM 500 W)
following embedding in OCT.
Consecutive serial cryosections of 5–6 mm thickness were
obtained from the middle (largest) portion of each samples, placed
on positively charged slides, dried in air for a few minutes and then
fixed with cold acetone. Two-four sections were stained with
Mayer’s hematoxylin for histopathologic examination.
After washing in 1X PBS and incubation in H2O2 at room
temperature to block endogenous peroxidase, the section were
incubated with diluted normal blocking serum prepared from the
Epigenetic Target Therapy for Prostate Cancer
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Figure 1. Qualitative and quantitative analysis of the distribution and effect of EMHVs treatment in DU145 prostate cancer cells.
Representative CLSM images of EMHVs internalization and released nanoparticle distribution (green fluorescence signal, B–E) into the host cell
cytoplasm at several time points are depicted. Naı¨ve cells (A) are reported as control. In (B), after 6 hours of treatment, an intact EMHV is present in
the cytoplasm (arrow). At 24 hours (C) the particles appeared to have been released from the EMHVs. In the pictures taken at 48 (D) and 96 (E) hours,
nanoparticles appear to have homogeneously distributed throughout the cytoplasm. Lack of toxic effect of erythrocyte drug delivery system
treatment was evaluated by FACS analysis (F) where cell profile of the treated cells (EMHVs) at selected time points show no significant changes in
sub-phase distributions with respect to control (CTRL).
doi:10.1371/journal.pone.0098101.g001
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species in which the secondary antibody is made. Slides were
incubated in humid chamber overnight at 4uC with primary
human reactive antibodies for Ki67 (clone SP6, rabbit monoclonal
antibody, Thermoscientific) at a dilution 1:200 and DNMT3b
(clone 52A1018, mouse monoclonal antibody, IMGENEX) at the
dilution 1:150. Following 30 min secondary biotinylated antibody
and 30 min Vectastain Elite ABC reagent the slides were then
incubation with peroxidase substrate solution (DAB). Slides were
counterstained with Mayer’s hematoxylin for 1 min, and mounted
in aqueous Mount Quick (Bioptica). Microscopic examination was
carried out from 2x to 40x magnification under an Olympus BX43
light microscope interfaced to a videocamera for digital acquisition
and imaging analysis (DP20 Olympus). The values of DNMT3b
and Ki67 positive nuclei were expressed as percentage of positive
or negative cells over the counting at least 500 total cells at 20x
original magnification.
Statistical analysis
The cell cycle phases are expressed as mean 6 SD of at least
n = 3. Three-Ways ANOVA were applied to compare the effect of
different treatments (CTRL, 6.8 mg 5-Aza-2’-dC; 120 ng 5-Aza-
2’-dC; 1.56108 A-EMHVs) on cell cycle phases (sub G1, G0-G1,
S, G2-M) and One-Way ANOVA was used to compare the effect
of A-EMHVs treatment at selected time points (24, 48 and
96 hours).
The apoptotic cells were expressed as mean 6 SEM of at least
n = 3. Statistical analysis was performed with One-Way ANOVA
independently for early and late apoptosis on log transformed data
to improve normalization. Pairwise comparisons were tested using
Tukey’s honestly significant difference criterion.
The in vivo results are expressed as mean 6 SEM of n = 6. One-
Way ANOVA was applied to compare the tumour mass reduction
in the evaluation of the xenograft implant after selected treatment
using data collected at the last injection. To describe tumour mass
reduction rate (50%) in mice after selected treatments, Kaplan-
Meier analysis was applied followed by log-rank test.
Ethics statements
Human red blood cells were obtained from transfusion bags
collected from anonymous healthy voluntary donors, which have
given their written informed consent carried out in accordance
with Italian Government law. It was not necessary the approval
from an institutional review board (ethics committee) since neither
direct human participation nor involvement of human studies
have been foreseen in this work. Samples have been provided by
Azienda Ospedaliera Universitaria Senese.
The preclinical study was carried out in strict accordance with
the recommendations in the Guide for the Care and Use of
Laboratory Animals of the International guidelines on handling of
laboratory animals and applying the 3Rs to experiments (in
accordance with NIH and European Commission recommenda-
tions).
The protocols for Animal Experiments were approved by the
Ethics Committee of the Marshall University (Huntington, WV,
USA) (Permit Number: # 458/2010) and by the Ethics
Committees of the Toscana Life Sciences and the Istituto
Superiore di Sanita` (ISS) on behalf of Italian Minister of Health
(Permit Number: # CNR-270111 exp1/prot1). Animal well-being
was monitored accordingly to Langford et al, 2010. [36] "
Figure 2. HPLC-MS chromatogram of the phosphorylated forms of 5-Aza-29-dC. (A) chromatograms for 5-Aza-29-dC mono-phosphate; (B)
di-phosphate (RT: 16.6); (C) tri-phosphate (RT: 16.5) and (D) internal standard CTP (RT: 16.5).
doi:10.1371/journal.pone.0098101.g002
Epigenetic Target Therapy for Prostate Cancer
PLOS ONE | www.plosone.org 5 May 2014 | Volume 9 | Issue 5 | e98101
Results
Characterization of novel anticancer formulation in
erythrocyte-based drug delivery system
To enhance the performance profile of 5-Aza-29-dC pro-drug,
with respect to chemical stability, pharmacokinetics and pharma-
codynamics, engineered magnetic erythrocytes carriers (EMHVs)
were used as drug delivery system (DDS). The kinetics of EMHV
DDS internalization and its toxicity as well as the efficiency and
efficacy of this novel anticancer 5-Aza-29-dC formulation were
tested firstly in vitro in hormone sensitive (LNCap) and resistant
(DU145) prostate cancer cells.
Internalisation of the EMHVs carrier into tumour cell in
vitro. The kinetic of EMHVs internalization into both LNCap
and DU145 prostate cancer cells was confirmed by Confocal Laser
Scanning Microscopy analysis (CSLM) by monitoring the
distribution of released fluorescent NPs (green) into the cytoplasm
of target cells (Fig. 1). An example of DU145 naı¨ve cells is shown
in Fig. 1A. Internalization is already taking place at 6 hours after
treatment, when EMHVs were found inside the cytoplasm of
DU145 cells. At this stage EMHVs still retain their intact
membrane and their content of NPs (Fig. 1B). Similarly to what
found in our previous work [33], after internalization the EMHV
membrane fuses with membrane of host cell releasing the
fluorescent content in the whole cytoplasmic space (Fig. 1C–E).
At the latest time points (48–96 hours) a wide spread fluorescence
of NPs is detectable in the cytoplasm although host cells appear
morphologically healthy and no cytotoxic effect is visible (Fig. 1D–
E).
Lack of toxicity of the EMHV carriers on cell
models. The toxicity of EMHV DDS against host cells was
assessed by analysing cell cycle phases of target cells. When treated
with unloaded EMHVs for 48 and 96 hours, no shift in LNCap
and DU145 cell phase distribution was detectable and cells
retained their normal cell cycle for the duration of the treatment
(Fig. 1F). This finding suggests that EMHVs drug delivery system
did not exert any toxic effect on cancer cells per se.
Chemical stability of 5-Aza-2’-dC into EMHV bioreactor
system (A-EMHVs). 5-Aza-2’-dC is a pro-drug and it requires
to be activated by phosphorylation to a nucleoside triphosphate
before exerting inhibition on DNA methylation [37].
Recently it has been shown that erythrocytes act as bioreactors
due to their enzymatic systems [34]. This makes them suitable for
encapsulation of pro-drugs that will subsequently be transformed
into the active drug [38]. Loading 5-Aza-2’-dC pro-drug into
EMHV bioreactor system was achieved according to a standard-
ized protocol (see materials and methods). HPLC-MS was used to
quantify the total amount of drug inside the DDS (A-EMHVs) and
to detect the presence of its active phosphorylated forms. The
chromatogram of samples incubated for 24 hours at 37uC
highlighted a mixture of different phosphorylated forms of 5-
Aza29-dC (Fig. 2). Di- and tri-phosphate forms of phosphorylated
5-Aza29-dC elute at RT 16.6 and RT 16.5 respectively (Fig. 2B
and 2C). Figure 2D shows the peak of cytidine thriphosphate
(CTP; RT: 16.5), an internal standard that we added to our
samples as control. It appears that the tri-phosphate form of 5-
Aza29-dC overbears the other phosphorylated forms proving the
high efficiency of EMHVs as bioreactors. We found that 1.56108
A-EMHVs accommodates about 120 ng of total drug and that the
Figure 3. The effect of A-EMHVs on the cell cycle arrest of LNCap, hormone sensitive and DU145 hormone refractory cells. 1.56108
A-EMHVs treatment, containing 120 ng internal 5-Aza-2’-dC, was compared with 6.8 mg free 5-Aza-2’-dC and 120 ng free 5-Aza-2’-dC treatments at 24
(top) 48 (middle) 96 (bottom) hours. Untreated cells were used as control (CTRL). In both LNCap (A) and DU145 (B) cell lines, A-EMHVs treatment
induced a significant enrichment in sub G1 cell distribution (black bars) already detectable at 48 hours after treatment (A and B middle panel,
respectively) that last up to 96 hours (*ANOVA p,0.05). Similar shift toward sub G1 distribution was also obtained using 6.8 mg of free 5-Aza-2’-dC
(1ANOVA p,0.05) but only detected at 96 hours. No shift in cell cycle distribution was detected for free 120 ng 5-Aza-2’-dC, not differing from
controls.
doi:10.1371/journal.pone.0098101.g003
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active phosphorylated forms of 5-Aza-2’-dC represents the 50% of
total loaded drug into the A-EMHVs.
The anti proliferative activity of A-EMHVs in vitro. The
anti-proliferative effect of A-EMHV in inducing cell cycle arrest
and apoptosis was tested in both prostate cancer models: hormone
sensitive LNCap cells and androgen independent prostatic cancer
DU145 cell line where traditional therapeutic approaches are
hampered by the lack of responsiveness to hormone therapy and
PSA antigen expression on the cell membrane.
The effect of 1.56108 A-EMHVs treatment, containing
approximately 120 ng internal 5-Aza29-dC, has been compared
with that of free 5-Aza-2’-dC used at the dose of 2.5 mM (total of
6.8 mg) scaled down from the therapeutic dose used in clinics. We
also compared the effect of the same amount of 5-Aza-29-dC
contained inside the A-EMHVs (120 ng) used as free drug
solution.
On hormone responsive LNCap cells (Fig. 3A), the A-EMHVs
treatment induced a significant enrichment in sub G1 suggesting a
possible activation of apoptotic response (Fig. 3A). This shift was
already detectable at 48 hours after treatment (Fig. 3A middle
panel) and reached statistic significance at 96 hours (ANOVA p,
0.05). A similar shift toward sub G1 distribution was obtained also
using 6.8 mg of free 5-Aza-2’-dC (ANOVA p,0.05), however this
dose is more than 50 times higher than the 5-Aza-2’-dC loaded
into the A-EMHVs. Moreover, the effect of 6.8 mg free 5-Aza-2’-
dC treatment seems to have a later onset comparing to A-EMHVs.
This is probably due to the fact that 5-Aza-2’-dC, encapsulated
into the EMHVs is readily turned into phosphorylated forms
Figure 4. The pro-apoptotic effect of A-EMHVs on LNCap, hormone sensitive and DU145, hormone refractory cells. 1.56108 A-EMHVs
treatment, containing 120 ng internal 5-Aza-2’-dC, was compared with 6.8 mg free 5-Aza-2’-dC and 120 ng free 5-Aza-2’-dC treatments at 96 hours.
Untreated cells were used as control (CTRL). In both LNCap (A) and DU145 (B) cell lines, A-EMHVs treatment induced a significant enrichment in early
apoptosis (*ANOVA p,0.05 and **ANOVA p,0.01, respectively). Using 6.8 mg or 120 ng of free 5-Aza-2’-dC, no effect in early apoptosis was detected
in any cell lines at 96 hours. Significant increase in late apoptosis response was observed in LNCap (C) and DU145 (D) after treatment with A-EMHVs
as well as with 6.8 mg of free 5-Aza-2’-dC (*ANOVA p,0.05 and ***ANOVA p,0.001, respectively), whereas no change in late apoptosis was detected
after lower free 5-Aza-2’-dC treatment at 96 hours in any of the cell lines.
doi:10.1371/journal.pone.0098101.g004
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Figure 5. Localized targeted in vivo distribution of EMHVs after systemic tail vein administration in mice. Representative X-ray images
of mice injected with EMHVs and treated with null (A and C) or 1,000 KOersted external static magnetic field (B and D) applied for 30 min in
correspondence of the abdomen, are depicted. After 1 hour from the injection, a rather sparse distribution of nanoparticles (white irregular shadow/
dots) was found inside metabolic organs and tissues exposed to null magnetic field (EMHVs-NMF, A sagittal and C frontal planes, respectively). After
exposure to the magnetic field (EMHVs-MF, B sagittal and D frontal planes, respectively), nanoparticles concentrated in the target tissue (abdomen)
resulting in a sharp intense signal (arrow).
doi:10.1371/journal.pone.0098101.g005
Figure 6. The anticancer effect of A-EMHVs treatment in vivo. Mass tumour growth curves for all experimental group are depicted in panel A
and B. The treatments are Control (CTRL, cyan); therapeutic dose (A1, red); low dose equivalent to that inside the erythrocytes (A2, purple); EMHVs
and no magnetic field applied (EMHVs-NMF, blue); EMHVs undergoing magnetic field (EMHVs-MF, yellow); loaded EMHVs and no magnetic field
applied (A-EMHVs-NMF, orange); loaded EMHVs undergoing magnetic field application (A-EMHVs-MF, green). In (A) LNCap xenograft, the most
significant mass reduction was measured both in A-EMHVs-MF and A1, while other treatments exerted intermediate effect with respect to controls
(One-Way ANOVA p,0.05 at time of the sixth injection). In (B) DU145 xenograft, mass showed a similar trend with A-EMHVs-MF and A1 treatments
being the most effective (One-Way ANOVA p,0.05). In C and D, Kaplan-Meier estimator curve was used to determine the percentage of treated mice
showing a reduction of tumour mass volume ($50%) during treatment. In (C) the trend of reduction is depicted for LNCap xenograft model: 100% of
animals show $50% tumour volume reduction after A-EMHVs-MF (day 7th) and A1 (day18th) treatments. In DU145 xenograft model (D), A-EMHVs-MF
(green) is the most effective anti-tumour treatment (e.g. CTRL or A2 vs A-EMHVs-MF, log rank = 4.52 at day 21st).
doi:10.1371/journal.pone.0098101.g006
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improving 5-Aza-2’-dC pharmacokinetics/pharmacodynamics.
Notably low doses of free 5-Aza-2’-dC (120 ng) did not exert
sub G1 shift effect and the cell cycle distribution profile did not
differ from controls up to 96 hours.
A similar trend towards sub G1 phase was described in
hormone resistant DU145 cell line (Fig. 3B) after either treatment
with A-EMHVs or 6.8 mg free 5-Aza-2’-dC at 96 hours (Fig. 3B
lower panel, ANOVA p,0.05) while no change in cell cycle was
detected after lower free 5-Aza-2’-dC treatment at any time points.
Because a hypermethylation of some tumour suppressor genes was
found in DU145, this suggests that a reprogramming of these drug
resistant cells towards susceptibility of cells to apoptosis was
achieved following epigenetic therapy.
To assesse if the treatments can induce the activation of pro-
apoptotic response, Annexin V test has been performed. The
analysis indicates that A-EMHVs exert a pro-apoptotic effect in
both prostate cancer cell lines (Fig. 4). In particular the A-EMHVs
treatment induced enrichment in early and late apoptosis at
96 hours after treatment (Fig. 4A and 4C) on LNCap cells,
reaching statistic significance in both cases (ANOVA p,0.05). A
similar result, but only for late apoptosis, was obtained using
6.8 mg of free 5-Aza-2’-dC (ANOVA p,0.05), whereas the level of
early apoptosis, induced by treatment, does not statistically differ
from control. A similar trend for both early and late apoptosis was
described in hormone resistant DU145 cells (Fig. 4B and 4D), after
treatment with A-EMHVs at 96 hours (ANOVA p,0.01 and p,
0.001, respectively). Using 6.8 mg of free 5-Aza-2’-dC, a significant
increase in late apoptosis was obtained, while no effect was
detected for early apoptosis. No change in apoptosis was detected
after lower free 5-Aza-2’-dC treatment at 96 hours in either of the
cell lines.
Characterization of novel anticancer formulation in vivo
To set-up an efficient and effective target epigenetic therapy for
solid tumours and overcome the obstacles represented by the use
of demethylating agents in clinical practice [39,40], we investigat-
ed the therapeutic potential of 5-Aza-29-dC (Decitabine) in a novel
anticancer formulation in vivo.
In vivo selective concentration of EMHV by magnetic
field. To verify that systemic intravenous (i.v) administration of
A-EMHVs could benefit the localised treatment of solid tumour,
we first assessed if EMHV DDS could be efficiently driven to reach
selected body compartments. Naı¨ve animals were i.v. injected with
1.56108 EMHVs. Immediately after injection a group of animals
was exposed to an external static magnetic field applied for 30
minutes to their lower lateral abdominal region (EMHVs-MF).
Control animal only received the injection and no magnetic field
was applied (EMHVs-NMF).
X-ray imaging, acquired 1 hour after the injection, shows
specific localization of the EMHVs in a mouse treated with
EMHVs in presence of magnetic field (Fig. 5B sagittal plane and
Fig. 5D frontal plane representative pictures). This animal displays
few well-defined localized bright spots in the abdomen, in
correspondence to the site of magnet application (1,000 KOer-
sted). No specific accumulation was evident in the control, treated
in absence of the magnetic field (EMHVs-NMF Fig. 5A and 5C,
sagittal and frontal planes, respectively), where a rather sparse
distribution of nanoparticles was found in the abdomen area,
apparently proximal to the liver and kidneys organs.
Effect of A-EMHVs on human hormone responsive LNCap
prostate cancer xenograft models. The therapeutic potential
of the novel 5-Aza-2’-dC anticancer formulation (A-EMHVs) was
investigated in vivo on animals bearing flank cancer xenografts. In
LNCap xenografts (Fig. 6A), a constant increased tumour mass
volume was measured in control animals (CTRL) as well as in the
groups treated with unloaded 1.56108 EMHVs either in absence
(EMHVs-NMF) or presence (EMHVs-MF) of static magnetic field.
In CTRL, volume reached 318.1065.90 mm3, while in EMHVs-
NMF and EMHVs-MF reached 257.80631.78 and
268.8467.72 mm3 respectively, confirming that unloaded
EMHVs delivery system does not induce any cytotoxic effect on
target tissues per se (see also Fig. 1F, in vitro data). Interestingly,
also the lower dose of free 5-Aza-2’-dC, (120 ng, A2), similar to
those entrapped into A-EHMVs, did not alter tumour mass
growth that increased up 296.19621.55 mm3, similar to controls.
On the contrary, a constant reduction of LNCap tumour mass
growth was observed in both A1 group treated with 85 mg free 5-
Aza-2’-dC (2.5 mg/kg) and the group treated with A-EMHVs in
presence of magnetic field (A-EHMVs-MF). More specifically, all
A-EMHVs-MF animals showed a reduction in tumour volume
as early as the second/third injection (A-EMHVs-MF
35.9166.29 mm3 and 27.1863.97 mm3) and this trend was
maintained up to the latest 6th injection (A-EMHVs-MF
15.9662.77 mm3). Similarly, a significant volume reduction was
measured in A1 group after fourth/fifth injection (A1
45.24610.94 mm3 and 21.3566.50 mm3) and this trend was
maintained up to the latest 6th injection (A1, 20.6364.59 mm3).
Therefore, although A-EMHVs-MF contains 700 times lower dose
(120 ng) than A1 therapeutic dose (85 mg/i.v.), it results signifi-
cantly more effective than the therapeutic dose (Two-Ways
ANOVA RM p,0.01).
In absence of static magnetic field (NMF), A-EMHVs treatment
exerts a strong cytostatic action, inhibiting the tumour growth
already after the first up to the latest injection (A-EMHVs-NMF
84.8762.09 mm3), although its effect is significantly lower in
respect to A-EMHVs-MF and A1 treatment (Two-Ways ANOVA
RM p,0.001).
The effect of A-EMHVs on non-responsive prostate cancer
DU145 xenograft model. Similarly to what described in vitro,
DU145 xenograft model is responsive to anti-cancer treatments
(Fig. 6B). As expected DU145 tumour mass grew steadily during
the entire duration of the experiment in CTRL, EMHVs-NMF
and EMHVs-MF groups (values at sixth injection: CTRL
312.54628.23 mm3; EMHVs-NMF 250.86619.25 mm3; EMHVs-
MF 224.50610.85 mm3). Moreover, also the low amount of free 5-
Aza-2’-dC was not sufficient to stop tumour growth (value at sixth
injection A2 group 248.94670.25 mm3). Nonetheless, tumour
volume reduction of circa 50% was visible after the third injection of
A-EMHVs in presence of magnetic field (A-EMHVs-MF
51.6568.65 mm3) up to the last measurement at time of the sixth
injection (A-EMHVs-MF 40.4365.29 mm3). Interestingly, this
reduction was not visible in A1 group. In the case of DU145
hormone resistant cells, treatment with therapeutic dose (85 mg/
injection) of free 5-Aza-29-dC (value at sixth injection A1 group
75.82621.9 mm3) was significantly less effective than carrier
delivered therapy, although the amount of injected free 5-Aza-2-dC
was 700 times higher with respect to those contained in A-EMHVs as
verified by Two-Ways ANOVA RM (A-EMHV-MF versus and A1,
p,0.05).
A-EMHVs in absence of magnetic field (value at time of sixth
injection A-EMHVs-NMF 127.88617.59 mm3) only exerted a
slight cytostatic activity on tumour mass and was significantly less
effective than A-EMHV-MF (Two-Ways ANOVA RM: A-
EMHV-NMF vs A-EMHV-MF p,0.001) and A1 treatment
(Two-Ways ANOVA RM: A-EMHV-NMF vs A1 p,0.05).
Estimation of mass reduction rate in vivo. The introduc-
tion of the magnetic field therefore re-enforces the anticancer
effect of A-EMHVs (A-EMHVs-MF vs A-EMHVs-NMF). This is
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depicted in the Kaplan-Meier estimator curve for both prostate
cancer xenograft models (Fig. 6C and 6D). We chose $50%
tumour volume reduction as the significant event to estimate and
analyse the percentage of animals that demonstrated this reduction
in time course.
In A-EMHVs-NMF as well as A2 and CTRL groups, the
treatments are not able to exert a beneficial reduction $50% of
tumour volume, neither in LNCap nor DU145 xenograft models.
A strong anti-cancer effect of the treatments was detected in
both A-EMHV-MF and A1 groups of LNCap xenograft as 100%
animals showed reduction of their mass volume more that 50% at
the 7th day and 18th day, respectively (log-rank test .3.84 A-
EMHV-MF or A1 vs CTRL). Similar although milder anticancer
therapeutic effect was measured in DU145 xenografts with 78% of
animals showing reduction of tumour volume of $50% in A-
EMHVs-MF group (log-rank test .3.84 A-EMHVs-MF vs
CTRL) and the 50% of A1 animals at day 21st. See also Figures
S1 and S2 showing representative images of mice bearing tumours
and intact severed specimens.
Therefore, comparing the new anticancer formulation with the
free administration of therapeutic dose either in hormone sensitive
and resistant forms of prostate cancer, the effect of this novel
Decitabine formulation on tumour volume reduction seems to
exert a stronger and faster effect with respect to drug free (A1)
Figure 7. Histological and immunohistochemical features of explanted xenografts. Representative sections of controls (CTRL), 120 ng of
free 5-Aza-2’-dC (A2) and A-EMHVs-MF treated animals. Top panels (A) show H&E stain at low power (2x original magnification) and high power (40x
original magnification, insets) micrographs. In B, immunohistological reactivity, positive for nuclear DNMT3b methyltrasferase (DNA
methyltransferase 3b) as a marker of tumour cells de novo methylation is shown (positive nuclei: dark brown, negative nuclei: blue. Original
magnification 10x and insets at 40x). In the bottom panels (C) proliferating tumour cells are visualized using Ki67 marker (positive nuclei: dark brown,
negative nuclei: blue. Original magnification 10x and insets at 40x).
doi:10.1371/journal.pone.0098101.g007
Table 1. Evaluation of cell proliferation after treatments.
CTRL A2 A-EMHVs-MF
absolute value % absolute value % absolute value %
DNMT3 + 93 15,7% 76 14,7% 64 10,4%
DNMT3 2 502 84,3% 575 88,3% 555 89,6%
total cell count 595 651 619
Ki67 + 124 20,3% 95 16,8% 37 6,5%
Ki67 2 488 79,7% 469 83,2% 535 93,5%
total cell count 612 564 572
Immuno-histochemical positivity for DNMT3b and Ki67. The results are expressed as cumulative number of and the percentage of reactive cells. Controls samples
showed the highest number of reactive cells in comparison to either A2 or A-EMHVs-MF treatments.
doi:10.1371/journal.pone.0098101.t001
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therapy although the amount of 5-Aza-29-dC contained into the
formulation in each injected dose is much lower that the free
administered drug.
Histological and immunohistochemical evidence of
epigenetic A-EMHV-MF treatment. A-EMHVs-MF induced
the most significant morphological changes in the tumour mass
severed from xenograft implants when compared with CTRL or
the equal dose (120 ng) of free 5-Aza-2’-dC treatment (A2). A first
qualitative analysis of tumour mass sections indicates that the A-
EMHVs-MF treatment induced a visible reduction of the slice
volume occupied by tumour cells associated with an extensive
replacement of death cells by fibrous tissue around the residual
tumour mass. Some fibrocytes and fibroblasts were visible within
the capsular tissue surrounding the tumour mass as well as
replacing the necrotic tumour cells.
A thorough investigation using standard H&E stain confirmed
that A-EMHVs-MF was the most effective treatment in promoting
tumour cells death as highlighted by loss of nucleic staining (right
inserts) and fibrous repair (Fig. 7 panel A). On the other hand, no
microscopically detectable changes in sparse fibrocytes and
fibroblasts were found across CTRL and A-EMHVs-MF samples
stained with H&E, suggesting that the A-EMHVs-MF treatment
did not induced any significant damage or toxic site effect on
normal cells.
As to confirm the epigenetic nature of the therapy, a higher
immunoreaction positivity for DNMT3b (DNA methyltransferase
3b) was found in tumour cells nuclei of control animals, (15.7%
positivity of a cumulative number of 595 cells, Table 1) (Fig. 7
panel B, CTRL), and in animals treated with 120 ng free 5-Aza-
2’-dC (14.7%, of 651 cells; Fig. 7 panel B, A2) as compared to
animals treated with A-EMHVs in presence of MF (10.4% of 619
cells; Fig. 7 panel B, A-EMHVs-MF). These results suggest that
loading 5-Aza-2’-dC into the erythrocytes (120 ng per dose) leads
to a more efficient inhibition of DNMT3b and in turn to increased
rate of tumour cell death. These data correlate with the
observation that nuclear immunoreactivity of the Ki67 cell
proliferating marker (Fig. 7 panel C) markedly decreases after A-
EMHVs-MF treatment (6.5% positive nuclei of a total nuclear
count of 572 cells) as compared to CTRL and A2 (20.3% and
16.8% positive nuclei, respectively), suggesting that A-EMHVs-
MF hampers cell replicating activity within tumour mass.
All together the in vivo data indicate that the administration of 5-
Aza-29-dC-loaded EMHVs in mice could be considered as a
locally effective epigenetic therapy. In fact it induced a significant
improvement in the pharmacokinetics of drug given that low
dosage of the demethylating agent was sufficient to reduce
expression of DNMT and to reprogram cell fate.
Discussion
The potential of novel target epigenetic therapy, based on the
use of engineered magnetic erythrocyte (EMHVs) drug delivery
system, has been demonstrated in this work both in vitro and in vivo
in hormone sensitive and resistant prostate cancer models opening
new therapeutic prospective for its future clinical application
against other solid tumours.
Using EMHVs, we were able to maximise the anti-cancer
effectiveness of 5-Aza-2’-dC demethylating agent and to improve
the bioavailability as well as pharmacokinetic and pharmacody-
namics of drug. 5-Aza-2’-dC loaded into the carriers exhibited a
significant anti-proliferative effect comparable only to the use of
much higher doses of free Decitabine. This effect is likely to be
related to the phosphorylation of Decitabine, critical step for
anticancer activity occurred inside the EMHVs that acted as
bioreactors as demonstrated by HPLC analysis. The shield
provided by EMHVs to the phosphorylated active form of drug
protects it from host enzyme degradation and promotes the pro-
drug to active drug transition. This would improve Decitabine
transient therapeutic effect and reduce inter-patient variability to
therapy response [41]. This is in good agreement with recent data
on Decitabine-loaded nanogels synthesized to deliver low amount
of drug to chemo-resistant breast cancer cells in vitro. In this work
the prolonged anti-proliferative effect of Decitabine was ascribed
to the sustained delivery rate achieved with the use of nanogels
that sustained DNMT1 depletion [21].
In vivo however, Decitabine epigenetic prolonged effect is strictly
dose schedule dependent and drug concentration and bioavail-
ability influence administration regime [27,39]. Here we were able
to further improve Decitabine pharmacokinetics in vivo, by
confining and concentrating the circulating drug-loaded EMHVs
at the site of action through the application of external static
magnetic field on animal xenograft tumours.
As shown in in vitro experiments, the fate of drug-loaded
EMHVs, reaching their target, is to fuse with and release their
content directly inside the host cells.
Kaplan-Meier estimator analysis demonstrated in fact a highly
significant reduction in growth of tumour mass in animals treated
with loaded EMHVs and magnetic field application, when
compared with free Decitabine treatment. This result derived
from two synergistic effects: the initial burst of delivery driven by
the magnetic field application and the subsequent cytostatic effect
that drug-loaded EMHVs provided as they remained in the blood
pool acting as a circulating reservoir of active drug that continued
to exert its anticancer activity after magnetic field removal.
The safety of the EMHVs delivery system was ascertained
neither in vitro nor in vivo as undesired toxic effect was detected. In
previous work we demonstrated that EMHVs are indistinguishable
from host erythrocytes therefore physiological RES processing is
awaiting EMHVs that might not be held by the applied magnetic
force. Toxicity tests in vivo demonstrated the safety of EMHVs
carrier in immune competent mice [34]. Thus the use of loaded
EMHVs would provide a low dose, safe targeted therapy effect
probably reducing possible toxic side-effects, such as granulocy-
topenia often observed in patients treated with Decitabine.
Moreover, the magnetic nanoparticles within engineered
erythrocytes are approved by FDA for use with Magnetic
Resonance Imaging (MRI) as a contrast agent to provide an
improved image of body organs and tissues in diagnostic routine.
It has been shown that these nanoparticles are eliminated
predominantly via the kidneys and their use appear in general to
be safe and well tolerated [42]. We demonstrated that EMHVs
carrying magnetic nanoparticles could be concentrated into
selected superficial or internal body districts by means of
application of a biocompatible external magnetic field thus
reducing the risk factors that could emerge by intravenous
administration of free magnetic nanoparticles. This no invasive
application uses similar magnetic force field employed in MRI
practice, suggesting the possibility of developing loaded EMHVs
formulation as a specific locally driven theranostic agent, thus
opening new therapeutic prospective for the use of 5-Aza-29-dC-
EMHVs formulation in other solid tumours.
Because aberrant DNA methylation associated with inappro-
priate gene silencing is a common feature of solid tumours, DNA
methylation inhibitors might contribute an alternative therapy
especially for those tumours no responsive to conventional
chemotherapy. Recent works identified aberrant methylation of
some genes in LNCap and DU145 cells and highlight the potential
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therapeutic value of demethylating agents in prostate cancer that
poor respond to conventional therapy [43,44].
Notably, we were able to tackle proliferation in prostate
hormone resistant cancer cells suggesting that the epigenetic
mechanisms are pivotal in development of resistant phenotype.
Future work should involve screening of reprogrammed methyl-
ation and reactivated gene expression in this unresponsive model
to correlate with anti-proliferative profile, which in turn would
result in halting of cancer metastatic fate. Although the exact
anticancer mechanism of 5-Aza-29-dC is controversial, however
our results suggest its possible role in the reduction of DNMT
expression. The majority of the reports used somatic cells to assess
anticancer activity of Decitabine at high dosage. There is evidence
that incorporation of 5-Aza-29-dC in DNA lead to the sequestra-
tion of DNMT enzymes and in turn to hypomethylation of specific
genes suppressing DNA repair activity [45]. Recently, a specific
sensitivity to low 5-Aza-29-dC dose (10 nM) by human embryonic
carcinoma cells (EC) was described in testicular germ cell tumours.
More specifically, hypersensitivity was correlated with high
expression of DNMT3b proper of embryonic and cancer stem
cells. In these cells, the early effect on DNMT3 depletion and gene
methylation was evident within 72 hours of treatment [19].
Similarly we found that the anti-proliferative effect due to loaded
EMHVs administration (120 ng 5-Aza-29-dC) in both LNCap and
DU145 was significantly higher at 24 and lasted up to 96 hours in
culture. A-EMHVs treatment resulted in a fast and strong shift of
cell cycle phase distribution towards sub G1, inducing the cell
cycle arrest. In fact apoptotic response was stronger after A-
EMHVs treatment, comparing free 5-Aza-29-dC conventional
treatment, likely due to the fact that EMHVs directly release and
enriched the therapeutic phosphorylated active drug inside the
cells.
Moreover, 5-Aza-2’-dC was also found to regulate gene re-
expression in a DNA methylation-independent manner through
the breaking up complex protein interactions by inhibition and
removal of DNMTs from the nucleus. It is likely that this
pronounced A-EMHVs-MF effect on prostate hormone responsive
and non-responsive tumour cells could be mediated by the
intrinsic direct inhibitory activity exerted by 5-Aza-2’-dC on the
DNA methyltransferases [37,46,47]. Indeed immunohistochemical
findings in specimens from in vivo xenografts suggested a specific
involvement of DNMT3b inhibition exerted by the low dose 5-
Aza-29-dC-loaded EMHVs (120 ng) in presence of magnetic field
causing apoptotic response on target cancer cells. A reduce
expression of DNMT3 was in fact found in tumour mass sections
after treatment with A-EMHVs-MF, while the same 5-Aza-29-dC
concentration administered free was not able to exert any changes
in immunohistochemical staining or cytotoxic effect.
Coincidently the expression of Ki67 pro-proliferative factor is
highly down regulated in tumour cells of animal group treated
with A-EMHVs-MF, suggesting that reprogramming of the
tumour suppressor gene methylation might take place and re-
establishing chemotherapy sensitivity would prompt those cancer
cells to respond to a subsequent conventional chemotherapy.
Interestingly, no morphological damages were visible in fibrocytes
and fibroblasts surrounding and infiltrating tumour mass suggest-
ing the A-EMHVs-MF treatment did not exerted any local toxicity
to normal cells.
EMHVs are versatile carriers that have been used to target the
delivery of different types of molecule and for the treatment of
diseases other that cancer. Recently, their use for a gene therapy in
a vascular restenosis models has been reported [48]. Similarly, in
this work erythrocyte-based delivery of bio-drugs resulted more
efficient than the delivery by other conventional vehicles. Up to
now the need for ex-vivo manipulations with RBCs, a relatively
limited shelf life, concerns related to the safety of donors matching
and blood-born infections have limited their use as DDS carriers.
The development of a personalized medicine for cancer or other
diseases based on the use of autologous loaded EMHVs is getting
nonetheless more and more feasible, as progress in modulating the
RBC membrane to produce transferable stealth donor RBCs have
been made. Indeed, the use of autologous blood (re-infusion)
would minimize the safety concerns. Loaded EMHVs may be
easily produced on the daily bases by self-donation of patients that
could lately receive the therapy with minimal discomfort and total
safety. This would encourage the ‘‘bench to bedside’’ translation of
innovative clinical approaches.
Conclusions
The scientific rationale for this investigation is the urgent need
to find new safe strategies for tackling common forms of cancer,
such as prostate cancer that often develops into metastatic and
untreatable forms. Increasing evidence suggests that epigenetic
events are causally implicated in prostate cancer development as
epigenetic silencing of androgen receptor expression has been
observed in 8% of primary prostate cancers. In the present work
we exploited the therapeutic potential of classic demethylating
agent Decitabine to induce tumour cell reprogramming by loading
it into an erythrocyte-based delivery system to improve pharma-
cokinetics and pharmacodynamics. This approach represents a
novel formulation of anticancer treatment that can be easily
localised at site of action by a non-invasive safe magnetic system.
Interestingly this novel Decitabine formulation might find new
application in unresponsive forms of carcinoma, such as hormone
refractory prostate cancer. As several challenges exist to success-
fully translate the outcomes from animal research to humans in a
clinical setting we foresee future investigation to confirm EMHVs
effectiveness in orthotopic animal model of cancer before
beginning studies in patients.
Supporting Information
Figure S1 Representative images of mice bearing
tumours and intact severed specimens of LNCap
xenograft groups after the sixth injection. CTRL animal
treated with 1X PBS; A1 animal treated with 85 mg 5-Aza-2’-dC
(2.5 mg/kg); A2 animal treated with 120 ng 5-Aza-2’-dC;
EMHVs-NMF animal treated with 1.56108 unloaded EMHVs
drug delivery system in absence of static magnetic field; A-
EMHVs-NMF animal treated with 1.56108 EMHVs containing
120 ng 5-Aza-2’-dC in absence of static magnetic field; A-
EMHVs-MF animal treated with 1.56108 EMHVs containing
120 ng 5-Aza-2’-dC and static magnetic field applied on tumour.
(TIFF)
Figure S2 Representative images of mice bearing
tumours and intact severed specimens of DU145 xeno-
graft groups after the sixth injection. CTRL animal treated
with 1X PBS; A1 animal treated with 85 mg 5-Aza-2’-dC (2.5 mg/
kg); A2 animal treated with 120 ng 5-Aza-2’-dC; EMHVs-NMF
animal treated with 1.56108 unloaded EMHVs drug delivery
system in absence of static magnetic field; A- EMHVs-NMF
animal treated with 1.56108 EMHVs containing 120 ng 5-Aza-2’-
dC in absence of static magnetic field; A- EMHVs-MF animal
treated with 1.56108 EMHVs containing 120 ng 5-Aza-2’-dC and
static magnetic field applied on tumour.
(TIF)
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